Temsirolimus

Temsirolimus (Torisel) is an intravenous medication used to treat advanced renal cell carcinoma (RCC), a type of kidney cancer. It is a type of drug known as a mTOR inhibitor, which works by blocking certain proteins and pathways in the body that are involved in cancer cell growth and division. Temsirolimus is usually used in combination with other medications, such as interferon or bevacizumab.

Temsirolimus is a medication used to treat a specific type of cancer: advanced renal cell carcinoma (RCC). Here's a closer look at its key aspects:

Purpose:

• Primarily targets advanced RCC, a cancer that originates in the kidneys.

Mechanism of Action:

• Belongs to a class of drugs called kinase inhibitors.
• Specifically targets a protein known as mammalian target of rapamycin (mTOR), which plays a crucial role in cell growth and division.
• By inhibiting mTOR, Temsirolimus disrupts the signaling pathway that fuels cancer cell proliferation, slowing down tumor growth.

Administration:

• Given intravenously (through a vein) typically once a week.

Side Effects:

• Common side effects include weakness, fatigue, swelling in the extremities, mouth sores, nausea, vomiting, and diarrhea.
• May also affect blood sugar levels and cholesterol levels.
• Increased risk of infections due to potential impact on the immune system.